Danaher : 2024 Q4 PresentationPresentationPresentationPresentation

Published: 2025-01-29 06:08:07 ET DHR

Danaher

Corporation

Fourth Quarter 2024 Earnings Release

January 29, 2025

Performance Summary: Revenue

Q4 Revenue

+2.0%

Core +1.0%

Acquisitions +1.5%

FX -0.5%

($ millions)

FY Revenue

Flat

Core -1.5%

Acquisitions +2.0%

FX -0.5%

($ millions)

Throughout this presentation, with respect to revenue performance, for the definitions of "Acquisitions", "Core" and "FX", please refer to Danaher's most recent Quarterly and Annual Reports filed with the SEC, which

are available in the "Investors" section of Danaher's website under the subheading "Financial Reports".

3

Performance Summary: Adjusted Operating Profit Margin

Q4 Adjusted Operating Profit Margin

+90 BPS

FY Adjusted Operating Profit Margin

-10 BPS

4

Performance Summary: Adjusted Diluted Net Earnings Per Common Share

Q4 Adjusted Diluted Net Earnings

Per Common Share

+2.4%

FY Adjusted Diluted Net Earnings

Per Common Share

-1.3%

5

Performance Summary: Free Cash Flow

Q4 Free Cash Flow Performance

+29.5%

FY Free Cash Flow Performance

+3.5%

($ millions)

($ millions)

6

Fourth Quarter 2024: Biotechnology

Revenue

+6.5%

Core +8.0%

FX -1.5%

Adjusted Operating Profit Margin

+200 BPS

($ millions)

7

Fourth Quarter 2024: Life Sciences

Revenue

+5.5%

Core +1.0%

Acquisitions +5.0%

FX -0.5%

Adjusted Operating Profit Margin

+320 BPS

($ millions)

8

Fourth Quarter 2024: Diagnostics

Revenue

-3.0%

Core -2.0%

FX -1.0%

Adjusted Operating Profit Margin

-170 BPS

($ millions)

9

Guidance

10

Disclaimer

Danaher Corporation published this content on January 29, 2025, and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on January 29, 2025 at 11:07:18.847.